Cargando…
Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)
BACKGROUND: Anthracycline use in metastatic breast cancer (MBC) is hindered by cumulative exposure limits and risk of cardiotoxicity. Pixantrone, a novel aza-anthracenedione with structural similarities to mitoxantrone and anthracyclines, is theorized to exhibit less cardiotoxicity, mainly due to la...
Autores principales: | Sideras, Kostandinos, Hillman, David W, Giridhar, Karthik, Ginos, Brenda F, Tenglin, Richard C, Liu, Heshan, Chen, Beiyun, Tan, Winston, Gross, Gerald G, Mowat, Rex B, Dueck, Amylou C, Perez, Edith A, Moreno-Aspitia, Alvaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074972/ https://www.ncbi.nlm.nih.gov/pubmed/35445723 http://dx.doi.org/10.1093/oncolo/oyab065 |
Ejemplares similares
-
Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)
por: Vera Aguilera, Jesus, et al.
Publicado: (2018) -
Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance)
por: Major-Elechi, Brittny T., et al.
Publicado: (2018) -
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
por: Chumsri, Saranya, et al.
Publicado: (2022) -
N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma
por: Halfdanarson, Thorvardur R, et al.
Publicado: (2022) -
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
por: Cheng, H, et al.
Publicado: (2014)